Trials / Completed
CompletedNCT00256204
A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease
A Multi Center, Double Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson's Disease Subjects
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,174 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- 30 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
A 2 phase study to evaluate disease progression in Parkinson's disease patients taking rasagiline
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rasagiline Mesylate | tablet, 1mg once daily |
| DRUG | Rasagiline Mesylate | tablet, 2mg once daily |
| OTHER | Placebo | Placebo |
Timeline
- Start date
- 2005-11-01
- Primary completion
- 2008-04-01
- Completion
- 2009-06-01
- First posted
- 2005-11-21
- Last updated
- 2012-01-12
- Results posted
- 2011-06-21
Source: ClinicalTrials.gov record NCT00256204. Inclusion in this directory is not an endorsement.